HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 05-06-2010, 07:02 PM   #1
Barbara2
Senior Member
 
Barbara2's Avatar
 
Join Date: Sep 2005
Location: South Dakota.
Posts: 621
Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER

Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies

Brussels, 6 May 2010 -- An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule.
The research, presented at the IMPAKT Breast Cancer Conference in Brussels, Belgium, could have an important impact on future clinical trial design and treatment strategies in HER2 over-expressing breast cancer.
The over-expression of HER2 --a molecule found on the surface of cells-- is an important marker in breast cancer. It had been associated with a poor outcome for women, but with the advent of anti-HER2 targeted agents, the prognosis for these women has improved.
But oncologists have known for some time that some HER2 over-expressing (HER2+) breast cancers do not respond to trastuzumab, currently the most commonly prescribed anti-HER2 agent.
Belgian and US researchers led by Dr Sherene Loi from the Institute Jules Bordet in Brussels set out to determine whether estrogen receptor status, another major biological variable in breast cancer, was involved.
"We looked at HER2+ breast cancer using gene expression data, array comparative genomic hybridization, cell lines and clinical data from nealry 2000 patients to determine if estrogen-receptor status plays a significant part in the biology of HER2+ breast cancer and response to anti-HER2 therapies," said Dr Loi.
"We found that estrogen receptor status of HER2+ breast cancer seems to be correlated with different responses to anti-HER therapies. Currently, the biological differences in the group of breast cancers that overexpress HER2 are largely unknown."
The results show that patients with ER+/HER2+ compared with ER-/HER2+ breast cancers may actually benefit more from drugs that inhibit the PI3K/AKT molecular pathway, as this could be the dominant biological pathway for tumor growth and progression, the researchers say.
"In contrast, our data suggest that inhibition of estrogen receptor --alone and in combination with such an inhibitor—could actually result in a worse outcome for the patient," Dr Loi adds. "This may help explain why researchers saw such a poor outcome in clinical trials where women with HER2+ cancer were given hormonal therapy alone."
__________________
Blessings and Peace,
Barbara

DX Oct 02 @ age 52 Stage 2B Grade 3 Mastectomy
"at least" 4.5 cm IDC 1+node ER+61% /PR-
Assiciated Intraductual component with Comedo Necrosis
Her2+ FISH8.6 IHC 2+
5 1/2 CEF Arimidex
Celebrex 400mg daily for 13 months
Prophylactic mastectomy
Estradiol #: 13
PTEN positive, "late" Herceptin (26 months after chemo)
Oct 05: Actonel for osteopenia from Arimidex.
May 08: Replaced Actonel with Zometa . Taking every 6
months.

Accepting the gift of life, I give thanks for it and live it in fullness.
Barbara2 is offline   Reply With Quote
Old 05-10-2010, 07:52 PM   #2
Debbie L.
Senior Member
 
Debbie L.'s Avatar
 
Join Date: Jul 2006
Posts: 463
Re: Estrogen receptor status of HER2+ breast cancer correlates with response to anti-

This is a report on the same study, but with a much more understandable (to me) explanation of why it's important. And if this idea panned out, what a different way of looking at (and perhaps dealing with) endocrine resistance in ER+HER2+ cancer. Apologies for the funky formatting - there's a lot of extra graphic stuff when copy/pasting from MedPage, even from a print page.
http://www.medpagetoday.com/MeetingCoverage/IMPAKT/19995


IMPAKT: Breast CA Receptor Tug-of-War May Impact Therapy
By Crystal Phend, Senior Staff Writer, MedPage Today
May 07, 2010


MedPage Today Action Points
  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

Review
BRUSSELS -- Breast tumors' estrogen receptors may interact with their HER2 receptors in a way that has implications for treatment of both, researchers found.

Tumors that were positive for both ER and HER2 preferentially activated a different set of biologic pathways compared with ER-/HER2+ cancers, found Sherene Loi, MD, PhD, of the Jules Bordet Institute in Brussels, and colleagues.

Greater activation of the PI3K/AKT pathway was seen in double-positive tumors, whereas ER-/HER2+ tumors favored EGFR/RAS/MAPK signaling, they reported here at the IMPAKT Breast Cancer Conference.

Loi speculated that one implication could be that HER2-targeted agents may work better without the hormonal therapy typically given to women who are ER+ and overexpress HER2.


Giving antiestrogen therapy would essentially switch them from ER+ to ER- by destroying the cells that rely on estrogen and thus switch the tumor's dominant pathway away from the PI3K/AKT pathway upon which trastuzumab (Herceptin) works, explained co-author Christos Sotiriou, MD, PhD, also of Jules Bordet Institute and conference co-chair.


"It's known that HER2 confers resistance to endocrine therapy, but this is now the opposite," he said in an interview. "The ER pathway may confer resistance to anti-HER2 therapy."


He cautioned that the results should be considered hypothesis generating, but suggested that it may be possible to optimize therapy for these patients by combining trastuzumab and lapatinib (Tykerb), which blocks both pathways.
ER-/HER2+ patients might be better suited to lapatinib rather than trastuzumab, Sotiriou added.


Regardless, anti-HER2 therapy now needs to be studied in ER+/HER2+ and ER-/HER2+ patients as distinct entities, conference co-chair Angelo Di Leo, MD, PhD, of the Hospital of Prato, Italy, said at a press conference.
Clifford A. Hudis, MD, of Memorial Sloan-Kettering Cancer Center in New York City and chair of the session, agreed that this should be marching orders for preclinical and clinical trials.


"We haven't quite done the experiment, but this would have really big implications," he told MedPage Today. "If it showed what they predicted, it would be really, really provocative."


Trastuzumab often overlaps with hormonal therapy in the postoperative adjuvant setting for these double-positive women, which might not be the right thing to do based on the results, he said.


He noted, though, that there is a range of ER positivity.
"The HER2s are going to be at the low end of ER positive," he said in an interview. "They're over the threshold to call positive, but they're really not the same positivity as a Luminal A."


Thus, the HER2 group "may be even more finely dividable than that," he added. "All of this represents a challenge. . . . We may be dividing these beyond the point of clinical practicality."


The researchers meta-analyzed data from 12 cohorts of patients for a total of 1,150 with gene expression data on ER status and 822 with HER2 status, about a quarter overall being HER2+.


Because 1,072 of these patients had been treated in the era before systemic therapies became available, the researchers examined their outcomes across breast cancer subtypes to approximate a natural history of the disease.
Among them, ER+/HER2+ had the worst relapse-free survival rates followed by ER+/HER2 Luminal B (P=0.06), triple negative (P=0.02), ER+/HER2 Luminal A (P=0.001), and ER-/HER2+ (P=0.01) cancers.


"While obviously these data likely represent a highly selected population, it's already begun to tell us that there seem to be significant biological differences by estrogen receptor status," Loi said at the conference.


Gene expression analyses showed that 24% of the whole genome differed in probe sets by ER status in HER2+ tumors while copy number differences were seen in 10% of the genome.


The level of HER2 mRNA expression was actually higher when ER status was negative (P=0.002), as was the epidermal growth factor receptor (EGFR) mRNA expression (P<0.001).


With regard to the functional impact of these differences on downstream pathway activation, ER positivity was associated with PIK3CAmt (as described by Loi) and AKT1 gene signaling, whereas there was a negative correlation with RAS (as described by Bild) and MAPK (as described by Creighton) gene signaling in HER+ breast cancer.


Among HER2+ cell lines, ER- cells showed reduced response compared with ER+ cells to both trastuzumab and lapatinib (both P<0.001).
ER-/HER2+ status was also associated with little response to AKT inhibition (P=0.001), unlike the dramatic sensitivity of ER+/HER2+ cell lines (P<0.001).
Loi reported that when the ER+/HER2+ cell lines were exposed to endocrine therapy (fulvestrant, Faslodex) -- a standard treatment for patients with this receptor status combination -- the addition of AKT inhibition blunted its impact on the disease (P<0.0001).


Altogether, these differences may yield different "pathway output dependency," which Loi said has different clinical implications.


"ER signaling may antagonize EGFR/RAS/MAPK signaling, leading to increased PI3K/AKT output in the double positives," Loi's group explained in the study abstract.
The researchers reported no conflicts of interest.
Hudis and Di Leo reported no conflicts of interest.

Primary source: IMPAKT Breast Cancer Conference
Source reference:
Loi S, et al "Molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) correspond to estrogen receptor status (ER) status" IMPAKT 2010; Abstract 970.





Debbie L. is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 12:16 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter